Advertisement

Topics

Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

11:38 EDT 17 May 2019 | OncLive

Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.

Original Article: Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

NEXT ARTICLE

More From BioPortfolio on "Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...